DWM
SAGE

Doyle Wealth Management’s Sage Therapeutics SAGE Stock Holding History

Doyle Wealth Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100
Closed -$18K – 639
2019
Q2 		$18K Buy
+100
New +$17.1K ﹤0.01% 533

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Doyle Wealth Management's SAGE Position: Q3 2019 in Review

Doyle Wealth Management sold out of Sage Therapeutics (SAGE) in Q3 2019, closing a stake of 100 shares — an estimated $18K sold.

Doyle Wealth Management first reported a position in SAGE in Q2 2019 and held it in 1 quarter. The position peaked at $18K in Q2 2019. 284 funds tracked by Wall St. Rank hold SAGE as of Q3 2019.

  • Doyle Wealth Management reported no remaining Sage Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Doyle Wealth Management sold 100 Sage Therapeutics shares in Q3 2019, an estimated $18K.
  • Doyle Wealth Management first reported a position in Sage Therapeutics in Q2 2019 and held it in 1 quarter.
  • Doyle Wealth Management's Sage Therapeutics position peaked at $18K in Q2 2019.
  • 284 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2019.

Based on Doyle Wealth Management's 13F filing for Q3 2019, filed 5 Nov 2019.